BACKGROUND: The Walking Impairment Questionnaire (WIQ) measures walking ability in daily life in patients with peripheral arterial disease causing intermittent claudication. We investigated the efficacy of sarpogrelate, a 5-HT2A receptor antagonist, in improving walking ability, as measured using new Japanese version of the WIQ. PATIENTS AND METHODS: A nationwide multicenter study was conducted at 80 institutions in Japan involving 586 patients with stable symptoms of intermittent claudication. Patients received open-label sarpogrelate 300 mg/day. A total of 419 patients were evaluated in the full analysis set (FAS) following the intention to treat principle, and 354 patients were evaluated in the per-protocol set (PPS). The FAS data are emphasized here. RESULTS: The mean follow-up was 27.7 ± 10.1 weeks. Each subscale of the WIQ score showed improvement after sarpogrelate treatment (p < 0.0001), and the resting ankle-brachial index increased significantly (p < 0.0001). The incidence of adverse reactions of the entire series of 559 patients was 4.83% (27 patients), but there were no clinically significant safety concerns. CONCLUSIONS: We have for the first time demonstrated that sarpogrelate may improve walking ability in daily life in Japanese patients with intermittent claudication. The drug had a good safety profile.
BACKGROUND: The Walking Impairment Questionnaire (WIQ) measures walking ability in daily life in patients with peripheral arterial disease causing intermittent claudication. We investigated the efficacy of sarpogrelate, a 5-HT2A receptor antagonist, in improving walking ability, as measured using new Japanese version of the WIQ. PATIENTS AND METHODS: A nationwide multicenter study was conducted at 80 institutions in Japan involving 586 patients with stable symptoms of intermittent claudication. Patients received open-label sarpogrelate 300 mg/day. A total of 419 patients were evaluated in the full analysis set (FAS) following the intention to treat principle, and 354 patients were evaluated in the per-protocol set (PPS). The FAS data are emphasized here. RESULTS: The mean follow-up was 27.7 ± 10.1 weeks. Each subscale of the WIQ score showed improvement after sarpogrelate treatment (p < 0.0001), and the resting ankle-brachial index increased significantly (p < 0.0001). The incidence of adverse reactions of the entire series of 559 patients was 4.83% (27 patients), but there were no clinically significant safety concerns. CONCLUSIONS: We have for the first time demonstrated that sarpogrelate may improve walking ability in daily life in Japanese patients with intermittent claudication. The drug had a good safety profile.
Authors: Eric P Brass; Richard Anthony; Frederick R Cobb; Isao Koda; Jenny Jiao; William R Hiatt Journal: J Am Coll Cardiol Date: 2006-11-28 Impact factor: 24.094
Authors: A T Hirsch; M H Criqui; D Treat-Jacobson; J G Regensteiner; M A Creager; J W Olin; S H Krook; D B Hunninghake; A J Comerota; M E Walsh; M M McDermott; W R Hiatt Journal: JAMA Date: 2001-09-19 Impact factor: 56.272
Authors: K Nishihira; A Yamashita; N Tanaka; R Kawamoto; T Imamura; R Yamamoto; T Eto; Y Asada Journal: J Thromb Haemost Date: 2006-01 Impact factor: 5.824
Authors: Julie R Menard; Hadley E Smith; Deborah Riebe; Christina M Braun; Bryan Blissmer; Robert B Patterson Journal: J Vasc Surg Date: 2004-06 Impact factor: 4.268
Authors: D Hoyer; D E Clarke; J R Fozard; P R Hartig; G R Martin; E J Mylecharane; P R Saxena; P P Humphrey Journal: Pharmacol Rev Date: 1994-06 Impact factor: 25.468